Biblio Discovery — Demo Discovery Service

68 results for "Stephan Weidinger"

Showing 1–20 · 0.63 seconds · RSS

  1. Journal Article

    Tolerability of Narrow-band Ultraviolet-B Phototherapy for Different Dermatological Diseases in Relation to Co-medications

    Anna M. Halupczok; Ann-Sophie Bohne; Sascha Gerdes et al.

    Acta Dermato-Venereologica, Vol. 104 · 2024 · English · DOAJ Scopus

    Phototherapy is an efficient therapy for a variety of skin diseases. Various drugs can cause photosensitivity and impact tolerability of phototherapy. The tolerability was investigated of narrowband ultraviolet-B 311 nm therapy in dependence on the underlying disease and long-term co-medication. A…

  2. Journal Article

    Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review

    Jonathan I. Silverberg; Eric Simpson; Melinda Gooderham et al.

    Dermatology and Therapy, Vol. 16 No. 2 · 2025 · English · DOAJ Scopus

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense itching, redness, and eczema. It significantly impacts the quality of life of affected individuals, often requiring long-term management strategies. Abrocitinib, an oral Janus kinase 1 (JAK1)…

  3. Journal Article

    An unusual granulomatous tinea due to Nannizzia incurvata in Germany without evidence of an acquisition from outside Europe and reduced itraconazole susceptibility

    Elisabeth Anke Schuldt; Karen Voss; Thomas Schwarz et al.

    Medical Mycology Case Reports, Vol. 51 · 2026 · English · DOAJ Scopus

    Nannizzia (N.) incurvata is a rare geo- and zoophilic dermatophyte with human infections only sporadically reported from Europe. We describe an atypical skin infection with granulomas from Germany confirmed by culture, PCR, and histopathology. A reduced susceptibility to itraconazole (unreported…

  4. Journal Article

    Type 2 Cytokine–Dependent Skin Barrier Regulation in Personalized 2-Dimensional and 3-Dimensional Skin Models of Atopic Dermatitis: A Pilot Study

    Hila Emmert; Franziska Rademacher; Matthias Hübenthal et al.

    JID Innovations, Vol. 5 No. 1 · 2025 · English · DOAJ Scopus

    Keratinocytes (KCs) from healthy donors stimulated with type 2 cytokines are often used to experimentally study atopic dermatitis (AD) inflammatory responses. Owing to potential intrinsic alterations, it seems favorable to use KCs from patients with AD. KCs isolated from hair follicles offer a…

  5. Journal Article Full text

    Compare and Contrast Meta Analysis (CCMA): A Method for Identification of Pleiotropic Loci in Genome-Wide Association Studies

    Hansjörg Baurecht; Melanie Hotze; Elke Rodríguez et al.

    PLOS ONE, Vol. 11 No. 5 · 2016 · English · PLOS Scopus

    In recent years, genome-wide association studies (GWAS) have identified many loci that are shared among common disorders and this has raised interest in pleiotropy. For performing appropriate analysis, several methods have been proposed, e.g. conducting a look-up in external sources or exploiting…

    Also available at: DOAJ

  6. Journal Article

    Patient preferences for atopic dermatitis treatments: a discrete choice experiment

    Shawn G. Kwatra; Peter Lio; Stephan Weidinger et al.

    Journal of Dermatological Treatment, Vol. 34 No. 1 · 2023 · English · DOAJ Scopus

    Background Patients with moderate-to-severe atopic dermatitis (AD) experience skin lesions and intense itch that substantially affect quality of life. Patients have choices among systemic AD treatments that offer varied benefit–risk profiles. Objective Measure patients’ willingness to trade off the…

  7. Journal Article

    Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

    Jonathan I. Silverberg; Eric L. Simpson; Andrew E. Pink et al.

    Dermatology and Therapy, Vol. 15 No. 2 · 2025 · English · DOAJ Scopus

    Abstract Introduction Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients…

  8. Journal Article

    Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study

    Felix Lauffer; Boris Bauer; Katharina Kreutzer et al.

    Dermatology and Therapy, Vol. 16 No. 9 · 2026 · English · DOAJ Scopus

    Abstract Introduction Minimal disease activity (MDA) has recently been introduced as comprehensive treatment target in atopic dermatitis (AD), integrating both clinician- and patient-reported outcomes. Evidence on the real-world feasibility and impact of achieving MDA on quality of life (QoL)…

  9. Journal Article

    Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study

    Stephan Weidinger; Tobias Schadeck; Felix Jacobs et al.

    Dermatology and Therapy, Vol. 15 No. 4 · 2025 · English · DOAJ Scopus

    Abstract Introduction Phase 3 clinical trials have demonstrated robust efficacy and favorable safety of upadacitinib for the treatment of atopic dermatitis (AD). However, real-world data are still sparse. The objectives of this study were to assess the effectiveness and safety of real-world…

  10. Journal Article

    Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

    Emma Guttman-Yassky; Thomas Bieber; Kenji Kabashima et al.

    Journal of Dermatological Treatment, Vol. 37 No. 1 · 2026 · English · DOAJ Scopus

    Purpose Achieving sustained on- and off-treatment disease control is an important therapeutic goal in atopic dermatitis (AD). This study evaluated achievement of off-treatment disease control in patients randomized to placebo following 12 weeks of abrocitinib 200 mg.Materials and methods In the…

  11. Journal Article

    A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study

    Adam Reich; Andrew Blauvelt; Stephan Weidinger et al.

    Dermatology and Therapy, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Introduction Amlitelimab (SAR445229, KY1005), a nondepleting anti-OX40 ligand monoclonal antibody, reduced lesions and pruritus in phase 2a and 2b trials in adults with moderate-to-severe atopic dermatitis (AD). Here, efficacy and durability of amlitelimab across body regions were…

  12. Journal Article Full text

    Tobacco Smoking Leads to Extensive Genome-Wide Changes in DNA Methylation

    Sonja Zeilinger; Brigitte Kühnel; Norman Klopp et al.

    PLoS ONE, Vol. 8 No. 5 · 2013 · English · PLOS Scopus

    Environmental factors such as tobacco smoking may have long-lasting effects on DNA methylation patterns, which might lead to changes in gene expression and in a broader context to the development or progression of various diseases. We conducted an epigenome-wide association study (EWAs) comparing…